Stock comparison
Haemonetics
Dr. Reddy's Laboratories Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
RDY
Dr. Reddy's Laboratories Limited
Market cap
$11.32B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | RDY | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 57C | HAE |
| Benjamin Graham | 85A | 72B | HAE |
| Philip Fisher | 60C | 61C | RDY |
| Peter Lynch | 54C | 55C | RDY |
| Joel Greenblatt | 31F | 46D | RDY |
| Charlie Munger | 54D | 49D | HAE |
| Terry Smith | 55D | 45D | HAE |
Side-by-side metrics
| Metric | HAE | RDY |
|---|---|---|
| Market cap | $2.98B | $11.32B |
| P/E (TTM) | 24.8x | 26.0x |
| EV/EBIT | 14.1x | 24.0x |
| ROIC (TTM) | 8.37% | 8.07% |
| Gross margin | 55.74% | 52.77% |
| Net margin | 7.29% | 12.76% |
| Revenue CAGR 5y | 7.65% | 13.31% |
| EPS CAGR 5y | 24.62% | 17.36% |
| Debt / Equity | 1.5x | 0.2x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 24.0x+41%
- EPS CAGR 5y24.62%vs 17.36%+29%
- Gross margin55.74%vs 52.77%+5%
RDY leads on
- Dividend yield0.6%vs 0.0%+100%
- Debt / Equity0.2xvs 1.5x+87%
- Market cap$11.32Bvs $2.98B+74%
- Net margin12.76%vs 7.29%+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.